Name: SCY-247
Brand: SCYNEXIS, Inc.

Health and Medical

SCY-770 is a novel, highly selective, clinical-stage direct AMPK activator under development as a new therapeutic approach for Autosomal Dominant Polycystic Kidney Disease (ADPKD). It directly activates AMPK, a key regulator of cellular metabolism, addressing the disease’s underlying metabolic abnormalities.

SCY-770

Science and Engineering

Biotechnology

SCYNEXIS, Inc.

New Jersey

Biopharma

Life Science

SCY-247 is a second-generation fungerp with enhanced pharmacological properties, developed for the treatment and prevention of severe and often fatal fungal diseases. It represents a significant advancement in combating antimicrobial resistance.

SCY-247

Other products/services from SCYNEXIS, Inc.

SCY-770

N/A